(Q46027726)

18 December 2017

title

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. (English)

1 reference

18 December 2017

main subject

phase III clinical trial

0 references

1 reference

1 reference

1 reference

Ihor Vynnychenko

7

0 references

Maciej Krzakowski

object named as

Maciej Krzakowski

5

0 references

Rodryg Ramlau

object named as

Rodryg Ramlau

6

0 references

0 references

3

Aleksandra Szczesna

1 reference

18 December 2017

author name string

Robert Pirker

1

1 reference

18 December 2017

Jose R Pereira

2

1 reference

18 December 2017

Joachim von Pawel

4

1 reference

18 December 2017

Keunchil Park

8

1 reference

18 December 2017

Chih-Teng Yu

9

1 reference

18 December 2017

Valentyn Ganul

10

1 reference

18 December 2017

Jae-Kyung Roh

11

1 reference

18 December 2017

Emilio Bajetta

12

1 reference

18 December 2017

Kenneth O'Byrne

13

1 reference

18 December 2017

Filippo de Marinis

14

1 reference

18 December 2017

Wilfried Eberhardt

15

1 reference

18 December 2017

Thomas Goddemeier

16

1 reference

18 December 2017

Michael Emig

17

1 reference

18 December 2017

Ulrich Gatzemeier

18

1 reference

18 December 2017

FLEX Study Team

19

1 reference

18 December 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

18 December 2017

published in

The Lancet

1 reference

18 December 2017

volume

373

1 reference

18 December 2017

issue

9674

1 reference

18 December 2017

page(s)

1525-1531

1 reference

18 December 2017

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

New molecularly targeted therapies for lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Customizing Cisplatin Based on Quantitative Excision Repair Cross-Complementing 1 mRNA Expression: A Phase III Trial in Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Erlotinib in previously treated non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Platinum-based chemotherapy plus cetuximab in head and neck cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Cetuximab in combination with carboplatin and docetaxel for patients with metastatic or advanced-stage nonsmall cell lung cancer: a multicenter phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960569-9

7 January 2021

10.1016/S0140-6736(09)60569-9

Identifiers

DOI

1 reference

18 December 2017

1 reference

18 December 2017